We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Device Developed Could Improve Cancer Detection

By LabMedica International staff writers
Posted on 02 Jun 2016
Circulating tumor cells (CTCs) are malignant cells that have escaped from a primary tumor into the bloodstream with the potential to form metastases at anatomically distant sites.

A newly developed method to isolate cancer cells that have escaped from a tumor could soon pave the way for improved diagnosis and treatment. More...
The simple process involves a special device that squeezes cells in a blood sample through tiny funnels, which drive the cancer cells and blood cells into separate streams based on differences in their size and softness.

Scientists at University of British Columbia (Vancouver, BC, Canada) used polydimethylsiloxane (PDMS) to fabricate the microfluidic device. Cell separation processes involved initially filling the microfluidic device using phosphate buffered saline (PBS) with 0.2% Pluronic F127 to prevent nonspecific adsorption of cells to the wall of the device. Whole blood samples from patients with metastatic castrate-resistant prostate cancer (mCRPC) and four healthy control donors were infused through the device through the sample inlet, while buffer solutions were infused through the buffer and oscillation inlets.

For the assessment of the role of cell deformability in separation performance the scientists measured the cell size, suspending the cell samples in PBS and visualized using an Ti-U inverted microscope (Nikon, Tokyo, Japan) and Nikon’s CCD camera DS-2MBW. The size of CTCs and leukocytes from mCRPC patients were measured from the bright field image of the separated cells in suspension by drawing a circle on the outer edge of each target cells. At least 25 CTCs and leukocytes were measured for each mCRPC data set.

The scientists were able to show in patients with metastatic castration-resistant prostate cancer, where CTCs are not significantly larger than leukocytes; CTCs can be captured based on deformability at 25× greater yield than with the conventional CellSearch system (Raritan, NJ, USA). Finally, the CTCs separated using this approach are collected in suspension and are available for downstream molecular characterization.

Kim N. Chi, MD, the director of clinical research at the B.C. Cancer Agency a co-author of the study said, “In the first study, the device was able to capture more than 90% of the cells. Importantly, in patient samples the device captured about 25 times the number of cancer cells and produced fewer false positives compared to the conventional CellSearch system, which also analyzes blood samples.” The study was published on April 7, 2016, in the journal Small.

Related Links:
University of British Columbia
Nikon
CellSearch

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Platelet Function Analyzer
PL-12
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.